Table 1.
Baseline characteristics of patients with a femoral neck T-Score ≥ −2.5 SD and ≤ −1 SD without prevalent vertebral fractures
| All patients | Excluding lumbar spine T-score <−2.5 SD | |||
|---|---|---|---|---|
| Placebon n = 309 | Risedronate 5 mg n = 311 | Placebon n = 146 | Risedronate 5 mg n = 147 | |
| Age (years)a | 64 (7.5) | 64 (7.5) | 63 (8.3) | 65 (7.0) |
| Femoral neck T-scorea, b | −1.84 (0.396) | −1.85 (0.406) | −1.77 (0.418) | −1.76 (0.398) |
| Height (cm)a | 159.8 (6.92) | 159.8 (6.05) | 160.6 (6.14) | 160.4 (6.32) |
| Weight (kg)a | 65.9 (11.92) | 66.8 (11.19) | 69.8 (12.91) | 69.6 (12.27) |
| BMI (kg/m2)a | 25.9 (4.54) | 26.2 (4.36) | 27.2 (5.1) | 27.1 (4.78) |
| Patients with prevalent OP-related nonvertebral fractures | 56 (18%) | 59 (19%) | 34 (23%) | 31 (21%) |
a Mean (standard deviation)
b Based on National Health and Nutrition Examination Survey III reference database